106 related articles for article (PubMed ID: 23826206)
1. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
2. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of TGF-β Receptor-2 Expression and Signaling through Inhibition of Na/K-ATPase.
La J; Reed E; Chan L; Smolyaninova LV; Akomova OA; Mutlu GM; Orlov SN; Dulin NO
PLoS One; 2016; 11(12):e0168363. PubMed ID: 28006004
[TBL] [Abstract][Full Text] [Related]
5. Prodigiosin Inhibits Transforming Growth Factor
Tai SB; Huang CY; Chung CL; Sung PJ; Wen ZH; Chen CL
Mol Pharmacol; 2024 Mar; 105(4):286-300. PubMed ID: 38278554
[TBL] [Abstract][Full Text] [Related]
6. TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll-like-receptor signalling.
Mohamed FEZA; Dewidar B; Lin T; Ebert MP; Dooley S; Meindl-Beinker NM; Hammad S
Int J Exp Pathol; 2024 Apr; 105(2):64-74. PubMed ID: 38328944
[TBL] [Abstract][Full Text] [Related]
7. Targeting the TGF-β signaling pathway: an updated patent review (2021-present).
Guo W; Liu H; Yan Y; Wu D; Yao H; Lin K; Li X
Expert Opin Ther Pat; 2024 Mar; 34(3):99-126. PubMed ID: 38648107
[TBL] [Abstract][Full Text] [Related]
8. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
Giannelli G; Villa E; Lahn M
Cancer Res; 2014 Apr; 74(7):1890-4. PubMed ID: 24638984
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
12. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
[TBL] [Abstract][Full Text] [Related]
13. TGF-β signaling pathway as a pharmacological target in liver diseases.
Zhang S; Sun WY; Wu JJ; Wei W
Pharmacol Res; 2014 Jul; 85():15-22. PubMed ID: 24844437
[TBL] [Abstract][Full Text] [Related]
14. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
Gueorguieva I; Cleverly AL; Stauber A; Sada Pillay N; Rodon JA; Miles CP; Yingling JM; Lahn MM
Br J Clin Pharmacol; 2014 May; 77(5):796-807. PubMed ID: 24868575
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
[TBL] [Abstract][Full Text] [Related]
16. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
[TBL] [Abstract][Full Text] [Related]
17. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation.
Nicolay NH; Sommer E; Perez RL; Wirkner U; Bostel T; Ho AD; Lahn M; Debus J; Saffrich R; Huber PE
Strahlenther Onkol; 2014 Oct; 190(11):1037-45. PubMed ID: 24863573
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transforming growth factor-β signals suppresses tumor formation by regulation of tumor microenvironment networks.
Tokizaki S; Podyma-Inoue KA; Matsumoto T; Takahashi K; Kobayashi M; Ibi H; Uchida S; Iwabuchi S; Harada H; Hashimoto S; Miyazono K; Shirouzu M; Watabe T
Cancer Sci; 2024 Jan; 115(1):211-226. PubMed ID: 37972575
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
